Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,030 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CSF Clear all
Completed Phase 2 Interventional Results available

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

NCT00006184
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Not applicable Interventional

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00801320
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Tumor collection
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 28, 2026, 6:24 AM EDT
Recruiting No phase listed Observational

Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy

NCT06075693
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
88 participants
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

NCT00023998
View directory record Official record
Conditions
Metastatic Osteosarcoma
Interventions
doxorubicin hydrochloride, cisplatin, methotrexate, leucovorin calcium, filgrastim, therapeutic conventional surgery, radiation therapy, etoposide, ifosfamide, trastuzumab, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

NCT00006011
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer
Interventions
Doxorubicin Hydrochloride, Cisplatin, Filgrastim, Pegfilgrastim, Paclitaxel
Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Adherus™ Dural Sealant in Spinal Procedures

NCT04498026
View directory record Official record
Conditions
Spinal Duraplasty
Interventions
Adherus Dural Sealant System, DuraSeal Exact Dural Sealant System
Device
Lead sponsor
Stryker Craniomaxillofacial
Industry
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Duarte, California • Sacramento, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00008125
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, carboplatin, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

NCT01387555
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions
JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Biological · Other
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
La Jolla, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 28, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF

NCT00208949
View directory record Official record
Conditions
Hematologic Diseases
Interventions
G-CSF, GM-CSF
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

NCT02683785
View directory record Official record
Conditions
Osteoarthritis
Interventions
GSK3196165, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

NCT00005576
View directory record Official record
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
Interventions
monoclonal antibody Ch14.18, isotretinoin, aldesleukin, sargramostim
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

NCT00514215
View directory record Official record
Conditions
Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery
Biological · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

NCT00322387
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions
G-CSF and plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Duarte, California • Beech Grove, Indiana • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 28, 2026, 6:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

NCT02282514
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 28, 2026, 6:24 AM EDT
Recruiting Phase 2 Interventional

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

NCT05419076
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Brain Metastases, Adult, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
Stereotactic Radiosurgery, Cerebrospinal fluid collection
Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 3 Interventional

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

NCT00003313
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
244
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 191 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 28, 2026, 6:24 AM EDT
Not listed Phase 2Phase 3 Interventional

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

NCT01094340
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Thalidomide
Drug
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

NCT00450450
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Secondary Myelodysplastic Syndromes
Interventions
allogeneic bone marrow transplantation, laboratory biomarker analysis, filgrastim
Procedure · Other · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
21
States / cities
Arcadia, California • San Francisco, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

NCT00006237
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
interleukin-2, filgrastim, interferon alfa, cisplatin, dacarbazine, vinblastine
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
296
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 197 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00787969
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cladribine, temsirolimus, Filgrastim, Pegfilgrastim
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
144
States / cities
Scottsdale, Arizona • Bloomington, Illinois • Canton, Illinois + 86 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 28, 2026, 6:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT04752163
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
DS-1594b, Azacitidine, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Leucovorin, Mesna, Methotrexate, Prednisone, Rituximab, Venetoclax, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Multiple Myeloma

NCT00019097
View directory record Official record
Conditions
Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions
autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan, sargramostim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
1995 – 2007
U.S. locations
3
States / cities
Little Rock, Arkansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 28, 2026, 6:24 AM EDT
Terminated Not applicable Interventional

A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)

NCT03471702
View directory record Official record
Conditions
Hydrocephalus, Hydrocephalus in Children, Tumor, Brain, Subarachnoid Hemorrhage
Interventions
Smart External Drain - SED
Device
Lead sponsor
Aqueduct Critical Care
Industry
Eligibility
Up to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 28, 2026, 6:24 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

NCT00005802
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cytarabine, etoposide, fludarabine phosphate, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 28, 2026, 6:24 AM EDT